English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Psilocybin Mushroom Dosage Explained: From Microdose to Heroic Dose
Before you weigh out a single gram of psilocybin mushrooms, there's a question worth sitting with: what are you actually after? A subtle nudge in mood while you go about your week? A long Saturday spent untangling something in your head? Or the full cosmic dismantling that some people spend years quietly preparing for? Because dosage isn't just a number on a scale. It's the difference between a pleasant afternoon and a life-rearranging encounter. And in the world of psychedelics and plant medicine, the gap between those two outcomes can be measured in fractions of a gram. So let's talk about what each range really looks like, where it tends to be useful, and the conditions that make each one safer. People who've worked with psilocybin for years tend to repeat the same line: set and setting are everything. They're not wrong. But dose is the third leg of that stool, and it's the one beginners get wrong most often — usually by aiming too high, occasionally by aiming too low and then doubling down halfway through. Mushrooms aren't standardized. Two grams of one strain can hit harder than three grams of another. Body weight matters. Empty stomach versus a recent meal matters. Tolerance from recent use matters. Even your mental state on the day will shift how a given amount lands. The numbers below are reasonable ballparks, not prescriptions — treat them as such. A microdose sits somewhere between a tenth and a twentieth of what would produce a recognizable psychedelic effect. In practical terms, that usually works out to around 0.1 to 0.25 grams of dried mushrooms. You shouldn't see walls melting. You shouldn't see anything, really. What microdosers do report tends to be subtler — a small lift in mood, easier focus on tedious tasks, a softer edge to anxiety, occasionally a bit more energy or creative flow. Some people swear by it for managing low-grade depression or stuck thinking patterns; others try it for a month and notice nothing at all. The research is still messy on this one, and placebo plays a bigger role than enthusiasts like to admit. The appeal is functional. You can microdose and still drive, work, parent, attend a meeting, go to the gym. It's the only mushroom dose that fits into a regular life without rearranging the day around it. Somewhere around 0.25 to 1 gram, you cross from sub-perceptual into actual psychedelic territory. The line isn't sharp. You'll know you've crossed it when colors start looking a little more saturated than usual, your body feels lightly buzzy, and you might find yourself giggling at things that aren't particularly funny. Low doses can swing either way emotionally. A bit euphoric for most. A bit anxious for some, especially if the setting feels wrong. This is the dose people bring to a quiet beach, a hike with one trusted friend, a small concert, or a long evening at home with good music. It's not the dose you want for a family dinner or anything requiring sharp executive function. Around 1 to 3 grams, things stop being subtle. Visual distortions get distinct — patterns crawling across textured surfaces, objects appearing to breathe, the famous geometric overlays when you close your eyes. Music can become physical. Time stretches; ten minutes might pass like an hour, or vice versa. Emotionally, this dose tends to crack things open. Gratitude shows up uninvited. So can sadness, paranoia, or anxiety if there's unresolved material floating around. Conversations with the right person can go astonishingly deep. Conversations with the wrong person, or in the wrong room, can spiral. This is also the range where people first start running into what the field calls a challenging experience. Not necessarily a bad trip — just one where something difficult surfaces and demands attention. A good sitter or a quiet space lets that process unfold instead of escalating. Three to four grams is generally classed as a high dose, and the character of the experience shifts. Hallucinations become more developed — closed-eye visions, scenes that play out like waking dreams, a sense of meeting something rather than just seeing patterns. Insights can arrive that feel non-negotiable, the kind of clarity that rearranges how you think about a relationship or a career or a long-held belief. Ego dissolution becomes possible at this range — the temporary loosening of the boundary between you and everything else. For some people that's the most healing thing they've ever encountered. For others it's terrifying. Often it's both, in the same hour. This is the dose most associated with the clinical psilocybin research on depression, end-of-life anxiety, and addiction recovery. It's also the dose where a trained sitter or facilitator stops being a nice-to-have and starts being genuinely important. Walking around a city center on three and a half grams of mushrooms is a recipe for disorientation at best and real danger at worst. The phrase comes from Terence McKenna, who suggested five grams of dried mushrooms in silent darkness as the threshold for a full mystical experience. Whether or not you find his cosmology persuasive, the dosage observation has held up: at roughly four grams and above, the experiences people report shift in character. Less about visuals. More about something that can only be described in the inadequate language of mysticism — oneness, dissolution, contact with something that feels intelligent, time folding in on itself. Heroic doses are not casual. They are not party doses. They are not something to try because a podcast made it sound interesting. The intensity is genuinely overwhelming, and even seasoned psychonauts describe being humbled by them. People emerge from heroic doses changed — sometimes in ways that take months to integrate. If you're considering one, the only responsible setting is a properly held container: a retreat, a ceremony, or a session with an experienced facilitator who knows how to support someone through the hardest stretches of a deep journey. Solo heroic dosing is how people end up in emergency rooms with stories that could have been avoided. A useful rule of thumb: as the dose climbs, the world around you needs to get smaller and more controlled. A microdose can survive almost any environment. A low dose wants company that's safe and an environment without sharp demands. A moderate dose wants a familiar room, a curated soundtrack, and someone you trust within reach. A high or heroic dose wants something closer to a sanctuary — dim light, a comfortable place to lie down, eye shades, music chosen in advance, and ideally a sober presence who's done this before. That's a lot of infrastructure for one person to assemble alone. It's part of why so many people end up choosing a retreat for their first deep psilocybin journey rather than trying to recreate ceremonial conditions in their living room. People sometimes pick a dose to prove something — to themselves, to a friend, to some imagined version of who they want to be. That's a bad reason. The mushrooms don't care about your bravado, and they will absolutely call your bluff. A well-chosen moderate dose in the right setting will do more for most people than a heroic dose taken because it sounded impressive on a forum. The other direction matters too. If you're working on something genuinely heavy — entrenched depression, addiction, post-traumatic patterns that haven't responded to years of other approaches — a series of cautious microdoses probably isn't going to touch it. There's a reason psychedelic-assisted therapy research uses the doses it does. For readers who want to explore this in a properly held setting rather than alone, a selection of curated psilocybin retreats can be browsed on our marketplace here. Whichever direction you choose, take the dose seriously — and take yourself seriously enough to choose the conditions that match it.
Psilocybin for Depression: What a Year-Long Johns Hopkins Study Actually Found
Picture this: two psilocybin sessions, spaced a couple of weeks apart, and a year later your depression scores are still down. That's the finding making the rounds out of Johns Hopkins, and if you're someone quietly considering a psychedelic retreat for a low mood that won't lift, it's worth understanding what the research actually says — and what it carefully avoids saying. The short version is genuinely promising. The longer version, which is the one you need if you're weighing a real decision, comes with caveats that the cleaner headlines tend to skip. Let's go through both. Researchers at the Johns Hopkins Center for Psychedelic and Consciousness Research followed 24 adults with major depressive disorder after giving them two doses of psilocybin alongside supportive psychotherapy. They'd already published earlier results showing the antidepressant effect held for two months. The new paper, in the Journal of Psychopharmacology, extends that follow-up to a full twelve. The numbers are striking. Average depression scores dropped from 22.8 — squarely in the severe range — to 7.7, which sits right at the threshold of no depression at all. That's not a marginal nudge. That's the kind of shift people normally chase across years of medication trials, talk therapy, and dose adjustments. And the participants got there with two guided sessions. No serious adverse events were reported as related to the psilocybin itself. Roland Griffiths, who led the work, framed it bluntly: where standard antidepressants need to be taken every day, often indefinitely, psilocybin may be able to do the job with one or two carefully held sessions. That's a different model of treatment entirely. Depression rarely travels alone. People who land on the idea of psychedelics — ayahuasca, psilocybin, ibogaine, San Pedro, the broader family of master plants — are often dealing with some braided combination of low mood, anxiety, trauma, and addiction. The same neural ruts that keep someone reaching for a drink at 9pm keep them reaching for the same dark thought at 3am. They're not separate problems wearing different costumes. That's part of why psychedelic-assisted recovery has caught so much attention. The effect isn't symptom suppression; it's something closer to a temporary loosening of the patterns themselves. Psilocybin appears to act on serotonin pathways in a way that interrupts the looping, self-referential negativity that defines a depressive episode. For some people, that interruption is enough to climb out. For others, it opens a window — and what they do with that window matters more than the medicine. This is the part the research gestures at but doesn't shout. About a third of the study's participants started an antidepressant during the follow-up year, and roughly 40% got some form of psychotherapy. The headline isn't psilocybin alone fixes depression for a year. The honest version is psilocybin, plus integration, plus often some combination of ongoing support, produced lasting change for most of the people in this small study. Not as snappy. More accurate. Standard SSRIs work for many people, partially work for many more, and don't work at all for a stubborn minority. Even when they help, they ask for daily commitment, side effects ranging from sexual dysfunction to emotional flattening, and a wind-down period that can be genuinely miserable. Psilocybin, in this trial, looks more like a procedure than a prescription — closer in shape to a surgical intervention than to a pill bottle. Two sessions. Substantial upfront cost in time, money, and emotional bandwidth. And then, in theory, you go on with your life. David Nutt of Imperial College London, who wasn't part of the Hopkins team, made the cost-efficacy point: the upfront expense of psychedelic therapy is high, but if the effects hold, it could compete with — or beat — the lifetime cost of conventional antidepressants. That math only works if the durability holds across larger and more diverse populations than 24 carefully screened volunteers, which is exactly what late-stage trials are now investigating. Here's where I want to slow you down, because this is where the gap between a research study and a real-world retreat opens widest. The Hopkins participants didn't take psilocybin on a beach in Jamaica or a jungle lodge in Peru. They took it in a controlled clinical room, with trained therapists, after multiple preparation sessions, with structured integration afterward. The medicine was one component of a careful protocol. Strip away the protocol and you're not running the same experiment anymore — you're running a different one, with different odds. A few things worth holding in mind if you're considering a psychedelic retreat for depression or addiction: None of this is meant to dampen the genuine promise here. It's meant to put the promise in scale. Psilocybin and the broader family of plant medicines look more and more like serious tools for serious problems. Tools, though. Not magic. The person holding the tool — meaning you, the support team, the facilitator, the therapist you see afterward — still does most of the work. The Hopkins paper sits inside a much larger wave. Compass Pathways is running late-stage psilocybin trials. MDMA for PTSD has been through multi-site Phase 3 work. Ibogaine continues to draw attention for opioid dependence. Ayahuasca research, slower and messier because of the ritual context, keeps producing intriguing signals around depression, addiction, and trauma. The picture forming across all of it is consistent: when paired with thoughtful psychological support, psychedelics can produce changes that standard pharmacology has struggled to match. The catch — and there's always a catch — is that the research settings bear little resemblance to most real-world settings. Underground use, casual recreational use, and even some retreat experiences strip away the elements that the trials suggest matter most. The medicine alone is not the whole story. It might not even be the most important part of the story. If you're someone reading this with a specific decision in mind — should I book a retreat, should I try psilocybin, should I look into ayahuasca for the thing I haven't been able to shake — let the research inform you without letting the headlines stampede you. The data is encouraging. The framework around the data is what makes it work. For readers who want to take this further, a range of carefully vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Depression is patient. It waits. The good news is that the tools available for working with it are finally getting more interesting than they've been in decades. The better news is that you get to be deliberate about how you use them.
Mixing Weed and Magic Mushrooms: What Actually Happens
Ask any group of psychonauts whether they've ever lit a joint mid-mushroom trip, and most will smirk before answering. The combination is common — almost a rite of passage in some circles — but that doesn't make it predictable, pleasant, or wise. Cannabis and psilocybin are two of the most-used psychedelics on the planet, and pairing them sits in a strange grey zone between folk wisdom and genuine risk. So let's actually talk about it. This isn't a recipe. It's a closer look at what each substance does, how they interact, and what's worth knowing before you decide whether they belong in the same evening. If you're researching this because you're curious about the broader world of psychedelics and master plants — maybe even considering a structured retreat down the line — the same principle applies: information first, decisions second. The short answer? Cannabis amplifies whatever's already happening. For some people, that means deeper visuals, looser thoughts, and a softer landing on the comedown. For others, it means a perfectly fine mushroom trip suddenly tips into a heart-pounding spiral that lasts an hour and feels like a lifetime. Same drugs, very different experiences — and that variability is exactly the problem. Psilocybin and THC also occupy different categories. Mushrooms are unambiguously psychedelic. Cannabis is harder to pin down — sometimes it acts like a mild hallucinogen, sometimes a depressant, sometimes a stimulant, depending on the strain, the dose, and the person. Stacking an unpredictable drug on top of an already unpredictable one is a recipe for surprises. Some are wonderful. Some are not. Psilocybin converts to psilocin in the body and binds to serotonin 5-HT2A receptors. The net effect is a flood of altered signalling and — this is the part researchers find most interesting — a quieting of the default mode network, the brain circuitry tied to your sense of a continuous, narrating self. When the DMN goes quiet, ego boundaries soften and sensory input gets louder. That's the classic psychedelic state. Cannabis works through a completely different system. THC mimics anandamide, an endogenous cannabinoid, and binds to CB1 receptors throughout the brain and body. CBD takes a subtler path — it slows the breakdown of anandamide and partially blocks CB1 receptors, which is why it can actually take the edge off THC's more anxious moments. Two different mechanisms, two different timelines, one shared bloodstream. Let's get the reassuring part out of the way first: neither psilocybin nor cannabis is physically toxic at recreational doses, and there is no known fatal interaction between the two. You're not going to die. That's not the risk anyone honest is worried about. The actual risk is psychological. Cannabis — especially high-THC, low-CBD cannabis — is surprisingly good at producing anxiety and paranoia in sober people. Now add a psilocybin trip, where your defences against anxious thinking are already lowered, and you have a setup where a small spike of weed-induced unease can balloon into a full panic loop. Racing heart, shortness of breath, that grim certainty that something is deeply wrong. None of it is dangerous in a medical sense. All of it feels awful in the moment. A few specific things worth flagging: If you've decided you want to try it anyway — and plenty of people do, with no drama — the consensus among more experienced users is consistent. Treat the night as a mushroom trip first. The shrooms are the main event. The cannabis is a small, optional accent, not a co-headliner. A reasonable approach looks something like this: Strain choice matters more than people give it credit for. High-CBD strains, or strains with a more balanced THC:CBD ratio, are far less likely to drop you into paranoia. The current trend toward 25%+ THC flower is the exact opposite of what you want on a trip. If you only have access to heavy indica or potent sativa, smaller doses or skipping the weed entirely is the smarter call. This question gets debated endlessly. There's no objectively correct answer, but here's the honest breakdown. Before. Some people smoke a little to ease pre-trip jitters. The risk is that cannabis anxiety becomes the seed of the entire experience, and you spend the next four hours trying to outrun a mood you set yourself. During the peak. Generally the worst option. The peak is already the most overwhelming part. Adding THC at peak is the most reliable way to push a manageable experience into a chaotic one. During the comedown. This is what most experienced users recommend. Two to three hours in, when visuals are softening and you're returning to baseline, a small amount of cannabis can extend the reflective, integrative quality of the experience without overloading your nervous system. This is also when sleep starts to matter, and indica strains can help close out the night. The next day. Maybe the most underrated option. The afterglow from psilocybin can last 24–48 hours, and a low-dose smoke the following evening sometimes brings back gentle echoes of the trip's clarity. No risk of a bad mix, all of the integration benefits. Mixing substances recreationally is a different universe from doing serious psychedelic work — and it's worth being honest about that distinction. People who combine weed and mushrooms at a music festival aren't pursuing the same thing as someone sitting in an ayahuasca ceremony or doing structured psilocybin sessions for depression. Both are valid. They're just different projects with different rules. If your interest in psilocybin is partly therapeutic — addressing depression, addiction, trauma, or just the sense that something in your life is stuck — the recreational mixing question becomes less interesting than the question of set, setting, and support. Most serious facilitators will tell you to leave cannabis out of the picture entirely during intentional work. It muddies the signal. It introduces a variable that has nothing to do with what you're trying to heal. And for people working through addiction specifically, the habit of layering one substance on another is often part of what they're trying to step away from. That doesn't make cannabis bad. It just means context matters. The joint with friends on a Saturday night and the cup of brewed mushroom tea with a trained guide are two different conversations, and treating them as interchangeable is how people end up disappointed in both. Can you mix weed and magic mushrooms? Yes. Should you? It depends entirely on who you are, what you're after, and how well you read your own warning signs. For some people, it's a pleasant amplification — funnier, deeper, more visual. For others, it's the thing that turns a beautiful afternoon into a few hours they'd rather forget. There's no way to know in advance which camp you're in until you try, and the prudent move is to err small: less weed, later in the trip, in a setting you trust. And if reading this has nudged you toward thinking about psilocybin more seriously — as a tool for healing rather than a Saturday-night curiosity — a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. The structured path is a very different animal from the recreational one, and for some people it ends up being the more useful door to walk through.
Types of Psychedelic Mushrooms: A Field Guide to Psilocybin Species and Fly Agaric
Walk into any conversation about psychedelics long enough and someone will say the word “mushrooms” as if it refers to a single thing. It doesn't. The world of psychedelic mushrooms is wider, weirder, and more geographically scattered than most people realize — over 180 known species, several different genera, and at least two completely separate chemical mechanisms producing the trip. If you're researching plant medicine seriously, or considering a psilocybin retreat, knowing what's actually inside the cap matters. This guide walks through the main families of psychedelic mushrooms, what makes them chemically distinct, and why the iconic red-and-white Amanita muscaria is its own strange beast — related to the others mostly in shape, not in spirit. A psychedelic mushroom is any fungus that contains a compound capable of meaningfully shifting perception, mood, or cognition. The vast majority owe their effects to psilocybin — a prodrug that the body quickly converts into psilocin, the actually-active molecule. Psilocin slots into serotonin receptors in the brain (the 5-HT2A site, mostly), and that's where the visuals, the time dilation, and the rearranging of inner furniture come from. People have been eating these mushrooms for a long time. Cave murals in Spain dating back roughly 6,000 years appear to depict Psilocybe hispanica. Desert rock art in Algeria, older still, suggests mushroom use stretching back seven to nine millennia. The Maya consumed Psilocybe cubensis. The Aztecs called certain species teonanácatl — “flesh of the gods.” Whatever you make of that lineage, mushrooms have arguably the longest documented relationship with humans of any psychedelic. The Swiss chemist Albert Hofmann — the same person who first synthesized LSD — isolated psilocybin and psilocin from Psilocybe mexicana in the late 1950s. That moment basically opened the modern scientific chapter on these fungi. Everything since, including the current clinical trials on psilocybin for depression, end-of-life anxiety, and addiction, traces back to that little Mexican mushroom. Most psychedelic mushrooms people will encounter — at a ceremony, at a retreat, in a research paper — belong to the genus Psilocybe. It's the largest grouping, with around 117 species, and contains nearly all the famous names. A few worth knowing: You'll also see Psilocybe baeocystis (bottle caps), Psilocybe pelliculosa, and Psilocybe aztecorum, the latter possibly being one of the original teonanácatl species. Each has its own potency profile, its own habitat, and its own enthusiasts. Psilocybe gets the spotlight, but psilocybin shows up in roughly a dozen other genera. The chemistry is the same — psilocybin, psilocin, sometimes baeocystin — but the mushrooms look and grow differently. Panaeolus is probably the most notable runner-up. Panaeolus cyanescens (sometimes called Copelandia cyanescens, or just “blue meanies”) is significantly more potent than your average cubensis. It's a tropical and subtropical mushroom, common in cattle pasture across Hawaii, parts of Mexico, and Southeast Asia. Panaeolus cinctulus — the banded mottlegill — is less potent but more widely distributed. Other genera include Gymnopilus, Pluteus, Inocybe, Hypholoma, and a handful of less common groupings. Inocybe aeruginascens deserves a quick mention because it's one of only two known natural sources of aeruginascin, a compound that some researchers have informally called “the CBD of magic mushrooms” for its apparent ability to soften the rougher edges of a trip. Whether that holds up under proper clinical scrutiny is still an open question. The point isn't that you need to memorize all this. The point is that “magic mushrooms” isn't a single substance — it's a category that includes everything from the laboratory-bred Penis Envy to obscure species growing on rotting logs in northern Spain. And then there's Amanita muscaria. The red cap with white dots. The mushroom in every video game, fairy tale, and Mario world. It is psychoactive — but it is not a psilocybin mushroom, and lumping it in with the others is a category error worth correcting. Amanita muscaria belongs to a genus that includes some of the most toxic fungi on Earth. The Amanitas as a group are responsible for the overwhelming majority of fatal mushroom poisonings worldwide. Fly agaric itself is technically classed as poisonous, though actual deaths from it are vanishingly rare and almost always involve massive overdoses or confusion with a more dangerous relative. The active compounds in fly agaric are muscimol and ibotenic acid, with smaller amounts of muscazone and muscarine. When you eat the mushroom, your body converts ibotenic acid into muscimol — the more potent of the two. Crucially, muscimol doesn't touch serotonin receptors at all. It acts on the GABA system, which is roughly the brain's brake pedal. That's why an Amanita experience is described so differently from a psilocybin one: less kaleidoscopic, more dreamlike, often sedating, sometimes outright dissociative. Effects can include: Indigenous shamans across Siberia — particularly the Koryak and Evenki peoples — have used fly agaric ritually for centuries, sometimes consuming it directly, sometimes drinking the urine of someone who already had (muscimol passes through the body largely intact, which is grim but pharmacologically interesting). It is, in every meaningful sense, a different medicine than psilocybin. If you're considering a retreat or ceremony, the practical question isn't usually “which species?” — most legitimate facilitators are working with Psilocybe cubensis or Psilocybe tampanensis truffles, and that's a known, well-mapped experience. The more useful questions are about dose, setting, screening, and integration support. A few things genuinely worth asking before you commit: The fly agaric question is a different conversation. Amanita muscaria retreats exist, but they're rarer, less standardized, and worth approaching with extra caution. The compound profile is genuinely different and the experience can be physically rougher. It's not for first-timers. One thing that gets lost in the listicle-style coverage of psychedelic mushrooms: these are old organisms with old relationships to people. The species names matter less than the relationship you build with whichever one you sit with. Curiosity is good. Reverence is better. A bit of fear, in the proper sense — taking the thing seriously — is probably the most underrated ingredient in a good psychedelic experience. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whichever direction you go, the mushroom you choose deserves the same care you'd give any teacher worth the name.
Ibogaine for Addiction Recovery: What Families Need to Know Before Booking
Somewhere in the world right now, a mother is sitting at her kitchen table reading message-board threads at 2 a.m., trying to decide whether to send her son to a clinic in Mexico because nothing else has worked. That's the real audience for any honest conversation about ibogaine. Not the wellness-curious. Not the psychonauts collecting experiences. The families and individuals who have run out of options and are weighing a plant medicine most of their doctors have never heard of. Ibogaine sits in a strange category. It's one of the most studied psychedelics for addiction recovery, and simultaneously one of the least talked about in mainstream coverage of plant medicines. People who go through it tend to describe it less as a trip and more as a reckoning. So before anyone clicks the booking button, here's what's actually worth understanding. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a small shrub native to the forests of Gabon and surrounding countries in west-central Africa. The Bwiti tradition has used iboga ceremonially for generations — for initiation, for ancestral connection, for healing crises that families can't solve on their own. The plant landed on Western radar in the 1960s when a young heroin user named Howard Lotsof took it recreationally and noticed, to his shock, that his withdrawal symptoms had vanished. The story of modern ibogaine treatment starts there. Pharmacologically, ibogaine is unusual. It interacts with multiple receptor systems at once — opioid, serotonin, NMDA, sigma — and its metabolite noribogaine lingers in the body for days. The practical effect, for someone in active opioid dependence, is often a near-complete interruption of withdrawal. That's not marketing language. That's what study participants and clinic data have repeatedly described. Whether the underlying craving stays gone is a separate question, and that's where retreats, integration, and aftercare matter more than the molecule itself. If you've been researching plant medicine for addiction, you've probably bumped into ayahuasca and psilocybin as well. They're not interchangeable. Ayahuasca tends to work through emotional and visionary processing — people often describe confronting memories, family patterns, the roots of why they started using. A psilocybin retreat can do something similar, with a gentler pharmacology and a shorter session. Ibogaine is different in one specific way: it appears to physically reset the opioid receptor system. People come off heroin, fentanyl, oxycodone, and methadone with their withdrawal flattened in ways that other psychedelics don't replicate. Anecdotally, it also helps with stimulant dependence — cocaine, meth — though the mechanism there is murkier. For alcohol, the evidence is mixed and personal. None of these is a magic bullet. The people who do best with any of them tend to be the ones who treat the medicine as the start of the work, not the finish. Here's the part where I'd rather be blunt than reassuring. Ibogaine is the most cardiotoxic of the commonly used plant medicines. It prolongs the QT interval — a measurement of heart electrical timing — and in people with undiagnosed heart conditions, electrolyte imbalances, or certain medication interactions, that can be fatal. There have been deaths. Most have happened at underground or under-equipped settings where pre-screening was inadequate or where someone was still using opioids when they took the dose. What a reputable ibogaine clinic does, at minimum: If a place doesn't do those things — if they wave off the EKG, if there's no doctor, if they're casual about your medication list — walk away. I don't care how good the testimonials are. The medicine is too strong to gamble with. People expect a psychedelic light show. That's not really what ibogaine delivers. The acute experience usually starts an hour or two after dosing and unfolds in phases. The first phase is often called the visionary state — eyes closed, lying down, a stream of images and memories that participants frequently describe as watching their life back, sometimes from unusual angles. There's not much choice involved. The medicine shows you what it shows you. The middle hours can feel physically demanding. Nausea, ataxia, light and sound sensitivity, a heavy body. This is not a dance ceremony. You will be on a mat or in a bed, with a quiet attendant nearby, for most of a day. The introspective phase follows — quieter, more verbal-thought-like, the part where the lessons of the visionary phase get processed. Then a long, sleepless tail of 24 to 48 hours where the body slowly recalibrates and rest is hard to come by. Most people who've done ibogaine for opioid dependence say the same thing afterward: the cravings, the constant background hum of I need to use, is gone or radically diminished when they wake up on the other side. That window is the gift. What you do with it determines whether the recovery sticks. Ibogaine is famous for its post-treatment window — sometimes called the grey day phase — when people report feeling unusually clear, motivated, free of the obsessive pull they lived with for years. That window can last weeks or months. It is not permanent on its own. The receptors come back. The life circumstances that fed the addiction are still there. The relationships, the job, the trauma underneath, the friends who still use — none of that got touched by the molecule. This is the place where so many ibogaine stories take a heartbreaking turn. Someone comes home from a clinic clear-headed, doesn't build the scaffolding (therapy, peer support, a new daily structure, a way to handle the first hard week), and within a few months they're back where they started, sometimes worse. Tolerance drops dramatically after ibogaine, which makes a relapse with the same old dose genuinely dangerous. If you or someone you love is considering this, the question to ask the clinic is not just how is the dosing session? It's what happens for the six months after I leave? Good programs will have an answer. They'll connect you to integration therapists, sometimes to follow-up booster sessions with a lighter medicine like 5-MeO-DMT or microdoses of iboga, sometimes to peer communities. If the answer is essentially you're on your own, treat that as a red flag. Ibogaine isn't for everyone who's struggling. People with a history of significant heart disease, long QT syndrome, recent cardiac events, untreated mental health conditions like active psychosis or bipolar I, or who can't get fully off long-acting opioids beforehand — these are situations where the risk-benefit math doesn't work, no matter how desperate things feel. A good clinic will turn applicants away. That's not them being difficult. That's them keeping you alive. For people who don't fit the ibogaine profile, other plant medicines or clinical pathways may be a better starting point. Sometimes the right move is a psilocybin retreat first, or trauma-focused therapy, or medication-assisted treatment to stabilize before considering anything else. The goal is recovery, not which substance gets credit for it. If you've read this far, you're probably not looking for permission. You're looking for clarity. So here's the honest summary: ibogaine is a serious medicine with a real track record in addiction recovery, particularly opioid dependence, and a real risk profile that demands medical screening and a structured environment. The people it helps tend to be the ones who do their homework, choose a clinic with proper safety standards, and commit to the integration work afterward. The people who get hurt are usually the ones who skipped one of those steps. Talk to people who've been through it. Read accounts that include the difficult parts, not just the success stories. Ask hard questions of any retreat you're considering. And if it feels right after all of that, the curated ibogaine and plant-medicine retreats discussed across the broader recovery space can be browsed on our marketplace here. Whatever you decide, the willingness to look this clearly at the choices in front of you is already part of the work.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Why Big Healthcare Money Is Quietly Backing Psychedelic Medicine
Something interesting has been happening in the back rooms of biotech finance, and most people booking a retreat in Peru next month have no idea. The same venture capital firms that bankrolled Moderna and Novavax are now writing checks to companies developing psychedelics into prescription medicines. That shift matters — not because Wall Street's blessing makes plant medicine more legitimate (it doesn't), but because it changes what's coming next. If you're researching ayahuasca, psilocybin, or any other psychedelic path for depression, addiction, or trauma, the story of who's funding what gives you a useful map. It tells you which compounds will reach clinics first, which retreats will face new competition from medical models, and which therapies remain — for now — only available outside the regulated system. Let's walk through what's actually happening. A few years ago, investing in psychedelic research looked like a hobby for eccentric philanthropists and crypto guys with a microdosing habit. That's no longer the case. A wave of specialist funds emerged first — small firms built specifically around psychedelic startups — and they did the unglamorous work of pushing early compounds through preclinical hurdles. They proved the science wasn't a joke. Now the bigger fish have arrived. Established healthcare venture capital firms with billion-dollar funds have started putting real money behind psychedelic biotech. These are the firms that fund late-stage clinical trials, the kind of trials that cost tens of millions and involve hundreds of patients across multiple sites. Without that capital, no psychedelic drug ever reaches an FDA approval. With it, the timeline shortens dramatically. The shift signals something subtle but important: psychedelics are no longer being treated as a curiosity. They're being treated as a drug development pipeline, with all the rigor and skepticism that implies. For the retreat-seeker, that's a double-edged thing. More research means better safety data and clearer answers about who benefits. It also means a medicalized future where some of these compounds become tightly regulated prescriptions rather than ceremonial sacraments. A handful of mainstream healthcare investors have made multiple bets in the space. Boston-based RA Capital — better known for funding vaccine makers — has backed at least three psychedelic-focused companies, including GH Research, Cybin, and Delix Therapeutics. All three are chasing mood disorders: depression, anxiety, and the stuck states that talk therapy and SSRIs can't always touch. Catalio Capital, a younger biotech-focused firm, has held positions in Atai Life Sciences and Compass Pathways through both their private and public stages. OrbiMed, a New York firm with stakes in more than eighty life-sciences startups, has put money behind Awakn — which is studying ketamine and MDMA for alcohol-use disorder — and Cybin, which is working on psilocybin and DMT-based compounds. Soleus Capital has stakes in Compass Pathways and Field Trip. If you've been following addiction recovery research, the Awakn investment is the one to circle. MDMA and ketamine for alcohol-use disorder is the kind of clinical work that could legitimately reshape how we treat addiction in the next decade. And it's being funded not by ideologues but by people who measure outcomes in spreadsheets. One company has attracted more healthcare-VC attention than the rest: GH Research, a Dublin-based outfit developing a treatment for treatment-resistant depression based on 5-MeO-DMT. That's the psychoactive compound traditionally extracted from the secretions of the Sonoran Desert toad — though clinical versions are synthesized, not harvested from amphibians. Why the unusual amount of investor enthusiasm? Two reasons, according to analysts who cover the company. First, the experience itself is short — typically under thirty minutes rather than the six-to-eight-hour marathon of a psilocybin session or the all-night ayahuasca journey. From a clinic-operations standpoint, that's enormous. Fewer staff hours per patient, faster turnaround, easier to scale. Second, the founders came in with substantial biotech credibility, which matters more than people in the plant-medicine world tend to admit. For readers who've sat with 5-MeO-DMT in ceremony, this medicalization can feel strange. The traditional context — drums, prayers, a guide who's worked with the medicine for years — gets stripped away in favor of a clinical room and a structured protocol. Whether that's a loss or simply a different valid container is one of the genuine debates in this field right now. Here's the practical takeaway. The medical pipeline and the retreat world are running on parallel tracks, and they will eventually intersect. Some predictions worth holding loosely: If your interest is in classic ayahuasca ceremony with experienced curanderos, the venture capital story barely touches your decision. Those traditions exist in a different ecosystem and will continue to. If your interest is psilocybin or MDMA for a specific clinical issue like depression or PTSD, you may want to weigh whether to seek a retreat now or wait for regulated options that could appear in the next handful of years. Retreats and clinics offer genuinely different things, and neither is universally better. A reputable plant-medicine retreat gives you traditional context, longer integration time, group ceremony, dietary preparation, and access to compounds and combinations that no clinic will ever offer. The costs are typically lower than medicalized therapy will be, though they're not cheap. A future FDA-approved psilocybin treatment will offer insurance coverage potentially, standardized dosing, screened therapists with malpractice insurance, and a legal framework that removes the risk of arrest or job consequences. What it likely won't offer is the cultural depth, the community, or the multi-day arc that lets the medicine work at the pace it wants to work. Both models have their failures too. Retreats vary wildly in quality, and there are operations out there with weak screening, undertrained facilitators, and no real integration support. Clinical models will have their own problems — the same brittleness that makes psychiatry frustrating for many people who go looking for help isn't going to vanish just because the molecule changes. Tracking who funds what is one of the more boring ways to predict where psychedelic medicine is heading, and one of the most reliable. When mainstream healthcare capital starts moving, regulatory approval tends to follow within a few years. The compounds with the most investor interest right now — psilocybin, MDMA, 5-MeO-DMT, ketamine — are the ones most likely to reach clinics first. For someone weighing a retreat decision today, the practical question isn't whether psychedelics work. The research increasingly suggests they do, for specific conditions, for specific people, under the right conditions. The question is whether the ceremonial route or the eventual clinical route fits your situation better — and that's a personal calculation involving your condition, your resources, your tolerance for uncertainty, and your relationship to ritual and tradition. If you want to explore what's currently available in the ceremonial and retreat world while the clinical options continue to develop, a curated selection of plant-medicine and psychedelic retreats can be browsed on our marketplace here. Whatever path you take, take it slowly, ask hard questions of any facilitator or clinician, and remember that the medicine is only part of the work.
MDMA-Assisted Therapy for PTSD: What the Research Actually Shows
Talk to anyone who lives with PTSD and you'll hear a version of the same exhausted story. They've tried the SSRIs. They've done the talk therapy. Some of it helped, a little. None of it did the thing they actually needed it to do — which was to let them sit with what happened without the floor falling out from under them. This is the gap that MDMA-assisted psychotherapy is starting to fill, and it's the reason the conversation around psychedelics and trauma recovery has shifted so sharply in the past few years. We are watching, in something close to real time, the slow legitimisation of a treatment that was banned from clinical use for nearly four decades. For readers weighing whether a psychedelic-assisted approach might help them or someone they love, here's what the picture actually looks like right now. The honest answer is that we haven't had a new pharmaceutical approach to post-traumatic stress disorder in roughly two decades. The standard toolkit — antidepressants, anti-anxiety medication, cognitive processing therapy, EMDR — works for a meaningful slice of patients. For everyone else, it's a long grind of trial and error, side effects, and the quiet despair of feeling like nothing is moving. Part of what makes PTSD so stubborn is structural. Trauma rewires the threat-detection part of the brain so that talking about the event re-triggers it. You can't think your way out of an alarm system. Many patients shut down, dissociate, or simply leave therapy because revisiting the memory feels worse than living around it. And among veterans the cost of this stuckness is staggering — the Department of Veterans Affairs has reported that roughly 18 American veterans die by suicide every day, with PTSD a major driver. So when results from a Phase 3 trial of MDMA-assisted therapy landed in Nature Medicine, the field paid attention. Around two-thirds of participants with severe PTSD no longer met the diagnostic criteria after treatment. That is not a minor effect. That is a number that makes career researchers double-check the data. This is the part most people get wrong, because the cultural image of MDMA is a sweaty warehouse and a water bottle. Clinical MDMA therapy looks almost nothing like that. In the trials, patients work with a co-therapist team — usually two clinicians, often one male and one female — across multiple preparatory sessions before they ever take the medicine. The dosing sessions themselves last six to eight hours. Patients lie down in a quiet room, often with an eye mask and headphones playing a carefully chosen playlist, and they go inward. The therapists are present the entire time, mostly quiet, occasionally checking in or supporting the patient as material surfaces. Then comes integration. After each medicine session, there are several non-drug therapy sessions to make sense of what came up. The standard protocol involves three MDMA sessions total, spaced weeks apart, with talk therapy threaded throughout. The drug is not the treatment. The drug opens a window; the therapy is what walks the patient through it. What participants consistently describe is something rare in trauma work — the ability to look directly at the worst thing that ever happened to them without flooding. The fear response gets quieter. Self-compassion gets louder. People report feeling more empathy, including toward themselves, and a strange capacity to hold grief, rage, and tenderness in the same hour without coming apart. Short answer: not yet for general clinical use, but the regulatory path is further along than most people realise. The FDA gave MDMA-assisted therapy Breakthrough Therapy designation, which is the agency's way of saying this looks promising enough to fast-track. Several jurisdictions have moved on their own — Australia, for example, has already approved prescribed MDMA for PTSD under tightly controlled conditions. In the United States, the road has been bumpier than advocates hoped. The FDA's advisory committee raised concerns in 2024 about trial design and the difficulty of blinding a study where participants obviously know whether they got the active drug. Additional research is underway. Most observers now expect a fuller approval picture to settle within the next couple of years, rather than the original optimistic 2023 target. For someone suffering right now, that timeline can feel maddening. A few legitimate options exist in the meantime: This is the part of the conversation that gets skipped in breathless coverage, and it matters. MDMA-assisted therapy is powerful, which means it can also be powerfully wrong for the wrong person. People with a personal or strong family history of psychosis or bipolar I are generally excluded from trials, because psychedelic-style experiences can destabilise vulnerable nervous systems. Certain heart conditions are a contraindication — MDMA raises blood pressure and heart rate. SSRIs and a handful of other medications interact badly with MDMA and have to be carefully tapered under medical supervision before any session, never on someone's own initiative. And then there's the psychological readiness piece, which no blood test will catch. Bringing buried trauma to the surface is the point of this work. If someone has no support system, no follow-up therapy lined up, and no plan for the weeks after the session — when integration is happening whether you're ready or not — they can end up more raw than when they started. The medicine is a catalyst. The container around it does the actual healing. MDMA is not a plant medicine in the traditional sense — it's a synthesized compound, first patented in 1912 and developed for psychiatric use in the 1970s. But the renaissance it represents is part of a broader shift. Psilocybin, ayahuasca, ibogaine, and 5-MeO-DMT are all moving through their own research pipelines and cultural reappraisals. The same basic insight underlies all of them: certain altered states, held inside a skilled therapeutic relationship, can shift things that conventional treatment cannot reach. This doesn't make psychedelics a cure-all. It doesn't make every retreat trustworthy, or every facilitator competent. What it does mean is that the question is no longer whether these medicines work — the evidence on that is increasingly clear — but how to deliver them responsibly, who they help most, and how to keep the work grounded as it scales. If you're sitting with PTSD, or watching someone you love sit with it, the most useful thing you can do right now is get informed. Read the published trials. Talk to a psychiatrist who actually knows this space. Look at ketamine-assisted options that are legal today. And if you're drawn to the broader world of psychedelic healing — including the plant-medicine traditions that have worked with trauma long before clinical trials existed — a thoughtfully chosen retreat can be one part of a longer recovery arc. For readers who want to take this further, a range of trauma-informed plant-medicine and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide slowly. The medicines aren't going anywhere, and the best work in this space rewards patience.
What a Kambo Ceremony Actually Feels Like: One Woman's First Time with the Frog
The first time I heard someone describe kambo, they called it “twenty minutes of dying, then you feel reborn.” That's the kind of sentence that either makes you walk away or quietly book a flight. If you've found your way to this article, you probably already know which camp you're in — you're curious about plant medicine, you've maybe done ayahuasca or are circling around it, and now you're wondering whether this strange frog-secretion ritual is something worth sitting for. This is one person's account of a first kambo ceremony, told honestly, with the gross bits left in. It's not a sales pitch. It's not a warning either. It's the kind of description I wish I'd had before I sat down on the floor, half-naked, and let a stranger burn my back. Kambo is the dried secretion of the giant monkey frog — Phyllomedusa bicolor — a bright green tree frog found across the western Amazon. Indigenous groups including the Matsés, Katukina, and Yawanawá have used it for generations as a hunting medicine, an immune tonic, and a way to clear what they call panema: bad luck, heaviness, stuck energy. The frog isn't killed. A practitioner mimics its call, the frog comes down, a small amount of secretion is scraped from its back, and it's released. The dried film is then reactivated with saliva or water and applied to small burns on the skin. What happens next is the part nobody can quite prepare you for. The peptides in the secretion — there are dozens of them, some of which have legitimate medical research behind them — flood your system within seconds. Your face flushes hot. Your heart pounds. Your blood pressure drops, then spikes. You may feel your tongue swell, your stomach turn, your skin tingle. Within a few minutes, most people purge — vomiting up the two or three liters of water they were asked to drink beforehand. The whole acute phase lasts twenty to forty minutes. Then, for many people, comes a strange lightness that's difficult to describe and even harder to forget. I'd been having a rough run of months. A long relationship had ended. Friendships were thinning out in that quiet way they do when you're shifting. I was raising kids, rebuilding a small business, and pretending I was fine. The standard self-care toolkit — lemon water, journaling, the occasional yin yoga class — had stopped touching it. A friend mentioned a practitioner staying at his house. I felt the pull. I've learned to trust that pull, even when I can't justify it. With ayahuasca, the call had been almost nagging for years before I finally went. With kambo, it was softer — more of a tap on the shoulder than a shout. I arrived on a Monday morning, fasted since the night before. The house sat behind a row of others in a quiet northern village, surrounded by flat green fields. My friend hugged me at the door and I burst into tears for no obvious reason. He just held on, smiled, said “good that you came,” and led me inside. Before any kambo touches your skin, you drink. A lot. At least a liter and a half, usually closer to three. Lukewarm, because cold water on an empty stomach during this process is its own kind of cruelty. The water isn't for hydration. It's the vehicle for the purge. When the secretion hits and the body decides to expel everything, you want something in there to expel. People who don't drink enough tend to dry-heave for an uncomfortably long time. People who drink enough release a clean wave and feel better fast. I was about two liters in when the practitioner walked in. I'd been picturing an older man with weathered hands, speaking Portuguese or Spanish I'd struggle to follow. Instead, a tattooed European in his late thirties walked through the door, whistling a tune I didn't recognize, smiled at me like we'd known each other for years, and pulled me into a hug. The cliché of what a healer “should” look like fell apart in about four seconds. That, I'd later realize, is part of the lesson. The application itself is quick and surprisingly low-drama. A thin stick is heated in a candle flame until it glows. The practitioner uses it to make small superficial burns — usually two or three on the upper arm for a first-timer, sometimes on the back, shoulders, or legs depending on what they read in your body. The burns sting briefly. They're not deep. They leave small round scars that fade over months, which many practitioners and participants think of as a kind of map. The reactivated kambo paste is dabbed onto the open burns. Within ten to twenty seconds, the medicine arrives. For me it came as heat — a flooding warmth that started in my belly and rose to my face. My lips felt thick. My pulse drummed in my ears. My head felt swollen, like I'd descended too fast in an aeroplane. What surprised me most was that I could stay present with it. I'd been bracing for terror. Instead I found something closer to intense observation. I'd given birth three times without medication. I'd sat in ayahuasca ceremonies. My body, it turned out, knew how to ride a wave of discomfort. I breathed. I noticed. I waited. The practitioner whistled the whole time — a melodic, repetitive song that genuinely did seem to hold the room. He squeezed my shoulders, pressed deep into points on my stomach that other bodyworkers had always zeroed in on, sprinkled water scented with something herbal across my skin. When the third burn went on, the nausea rose fast. I leaned over the bucket and let it go. A startling volume of water came out. Then I was empty, and quiet, and the heat in my head began to recede. This is the question that matters most if you're reading this and thinking about booking something. Kambo is generally well-tolerated by healthy adults, but it is not without risk, and the risks are not theoretical. The single most important variable is who's holding the space. Ask about training lineage. Ask how many ceremonies they've facilitated. Ask what they screen for. Ask what happens if something goes wrong — is there a phone signal, a vehicle, a plan? A practitioner who waves these questions off is one to walk away from. People come to kambo for a lot of reasons. Chronic inflammation. Depression that won't lift. Lyme disease and other lingering infections. Brain fog after a hard year. A sense that something is stuck and won't move. The research on the peptides — particularly dermorphin, deltorphin, and phyllocaerulein — is genuinely interesting, but the clinical picture is still thin. The traditional framing of kambo as a cleansing and clearing medicine has held up better than most of us cynical Westerners expected. What kambo isn't: a magic eraser. It won't undo years of trauma in a single session. It won't replace therapy, integration, or the slower work of changing your life. People who treat it as a quick fix tend to come away disappointed. People who treat it as one tool in a wider practice tend to come away grateful. For those weighing whether plant medicine of any kind might help with addiction, depression, or stuck patterns, kambo is often a useful early step — physically intense but shorter and less psychologically disorienting than ayahuasca, ibogaine, or psilocybin. Some people use it as preparation before a bigger ceremony. Others find it's enough on its own. Within an hour of the ceremony ending I was eating fruit, laughing about something inconsequential, and feeling lighter than I had in months. Not euphoric — that word always sounds like marketing. Just lighter. The static in my head had quieted. The grief I'd been carrying was still there, but it had room to breathe around it. That clarity held for about a week before normal life began to reassert itself, which is roughly what experienced participants had told me to expect. Kambo isn't subtle, but its gifts are. You don't get a personality transplant. You get a window. What you do with the window is the actual work. If you've read this far and something in you is still leaning forward, that's worth paying attention to. Curated kambo ceremonies and broader plant-medicine retreats can be browsed on our marketplace here, with practitioner backgrounds and screening protocols laid out so you can make a clear-eyed choice. Whatever you decide, do the boring due diligence first — the frog will still be there when you're ready.
How to Take Magic Mushrooms: 5 Methods Compared for First-Time Trippers
Here's something most first-timers don't realise until they're already an hour deep: how you take psilocybin mushrooms changes the trip almost as much as the dose. Same gram of cubensis, two different methods, two completely different afternoons. One person is quietly weeping at a houseplant. The other is throwing up behind a tree, wondering what went wrong. The difference usually comes down to preparation. Magic mushrooms — and the broader family of plant medicines and psychedelics that people turn to for healing, addiction recovery, or deep soul exploration — are not one-size-fits-all. The method of consumption shapes how fast the come-up hits, how intense the peak gets, how long you're out there, and (crucially) whether your stomach behaves itself. So before you crunch down on a dried cap, it's worth knowing your options. Short answer: yes. Longer answer: the chemistry is genuinely different depending on how the psilocybin gets into your bloodstream. Psilocybin itself isn't psychoactive — your body has to convert it into psilocin first, usually through stomach acid and a stop at the liver. Anything that speeds up, slows down, or sidesteps that process changes the character of the trip. Eat on an empty stomach and the come-up is fast, sometimes uncomfortably so. Eat after a big meal and the whole thing arrives gently, peaks lower, and fades sooner. Add lemon juice and you've effectively done the conversion outside your body, which means the trip hits like a freight train. None of these are right or wrong — they're tools. The question is what kind of experience you actually want. A quick word on dosing before we get into methods. Mushrooms are not something you can redose halfway through. Your serotonin receptors downregulate fast once psilocin shows up, so a second helping forty minutes in mostly just gives you a stomach ache. You get one shot to land the dose right. As a rough guide for dried cubensis: These numbers shift wildly depending on the strain, how fresh they are, your body weight, and what you ate for breakfast. When in doubt, go lower. You can always do it again next month. The most basic method and, for a lot of people, still the best. You take the mushrooms, you chew them slowly and thoroughly, you swallow. That's the whole technique. The taste is — let's be honest — not great. Earthy, slightly metallic, with a texture somewhere between cardboard and old sponge. But chewing matters. The more you break the cell walls down before swallowing, the faster your gut can extract the goods. People who bolt them down whole often wonder why the come-up took two hours. People who actually chew can feel something within twenty to thirty minutes on an empty stomach. The trip from this method tends to be the most balanced — slower to build, longer to taper, slightly more body-load than the cleaner approaches. If you're going to a forest, a beach, or anywhere you'd rather not be carrying drug paraphernalia, this is your friend. Tea is what a lot of experienced trippers default to, and it's the method most ceremonial settings prefer too. There are two big advantages. First, the taste is far more manageable — throw in some ginger, lemon, honey, whatever — and you can actually finish your dose without gagging. Second, you're not eating the chitin. Chitin is the fibrous stuff that gives mushroom cell walls their structure. It's also a major cause of the famous shroom nausea. By steeping rather than eating, you extract the psilocybin into the water and leave most of the chitin behind in the grounds. People with sensitive stomachs swear by this method. The basic process: heat water to around 70°C — no hotter, because high heat degrades psilocybin — grind your mushrooms fine, steep for about twenty minutes, strain, drink. A squeeze of lemon juice into the tea kicks off some of the psilocybin-to-psilocin conversion before you drink it, giving you a slightly faster and sharper come-up without the full intensity of a lemon tek. Onset is usually faster than chewing, peak comes on cleaner, and the overall arc tends to feel less heavy on the body. Capsules are the method of choice for two very different groups: people who genuinely cannot stand the taste, and people who microdose seriously and need to know exactly what they're taking every time. To make them, you need a coffee grinder, milligram-accurate scales (not the kitchen scale you weigh flour on — get a proper jeweller's scale), and empty gelatin or veggie capsules. Grind your dried mushrooms to a fine powder, weigh out each dose, fill the capsules. Most size 0 capsules hold roughly half a gram of mushroom powder, so a full ceremonial dose means swallowing several at once. The trade-off is onset speed. Capsules have to dissolve before anything happens, which adds maybe twenty extra minutes to the come-up. For a microdosing regimen — where you're taking 0.1 to 0.3 grams a couple of times a week and trying to function normally — that's a feature, not a bug. The trip is gentle, the body load is light, and you can carry a dose discreetly in a vitamin bottle. Mushroom chocolate is the most popular edible by a wide margin, and the pairing isn't new — the Aztecs were combining psilocybe with cacao long before anyone wrote about psychedelics. There's a folk belief that the MAO-inhibiting compounds in raw cacao potentiate the trip, though the evidence for this in normal doses is thin. What chocolate definitely does is mask the taste and make dosing more pleasant. Other edibles are possible — honey, energy balls, smoothies — but two warnings. First, heat above roughly 70°C will degrade the psilocybin. So baking your mushrooms into a brownie is mostly just wasting them. Second, any meaningful amount of food in your stomach during the trip will mute the experience. Mushroom pizza is mostly a joke; if you want a real psychedelic journey, don't eat a meal alongside it. The right way to make chocolate is to melt good-quality dark chocolate low and slow (a double boiler, off the heat once it's liquid), stir in your ground mushroom powder once the chocolate has cooled to lukewarm, then pour into moulds. Dose each piece deliberately so you know what you're eating. If you want the most intense version of the trip in the shortest amount of time, lemon tek is the way. You grind the mushrooms fine, cover them in fresh lemon juice (the citric acid does the work that your stomach would normally do), let it sit for fifteen to twenty minutes, and then take the whole shot — pulp, juice, and all. What you're doing is converting the psilocybin to psilocin before it enters your body. That means when you swallow it, the active compound is already there, ready to cross into your bloodstream. Onset is fast — sometimes fifteen minutes — and the peak hits hard and clean. Many people describe lemon-tek trips as more visual, less nauseating, and shorter overall, with the whole thing wrapped up in three to four hours instead of six. The catch: it is intense. People who handle two grams chewed will often find one and a half grams lemon-tekked is more than enough. If you're new to this method, drop your usual dose by a third and see how it goes. You can't pull back once you've drunk it. Method doesn't matter if the timing is wrong. There are situations where the kindest thing you can do for yourself is put the bag back in the drawer. Whatever method you choose, the same basics apply. Eat lightly four to six hours beforehand. Have water, fruit, and a blanket within reach. Pick music you trust — a curated playlist beats whatever shuffle throws at you. Have a sober sitter if it's your first time, or at least someone who knows what you've taken and can be reached. And give yourself the whole next day to come down properly; this isn't something to do on a Sunday evening before a Monday meeting. For people exploring psilocybin as part of something bigger — addiction recovery, depression that hasn't responded to other approaches, the kind of stuck patterns that come up when you read about master plants and wonder if they might help — a structured retreat is worth considering. The difference between tripping alone in your bedroom and sitting with experienced facilitators in a prepared container is enormous, and not just in terms of safety. Integration support afterwards is where most of the real change happens. If any of this has caught your attention and you'd like to take the exploration further, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever route you take — solo and slow, or in ceremony with others — go gently, dose conservatively, and respect what these mushrooms are actually capable of doing.
Ibogaine Aftermath: What to Do When Side Effects Linger Past Two Weeks
Two weeks after an ibogaine session and you still feel… off. Heart fluttering when you climb stairs. Sleep that comes in shards. A weird metallic fatigue that no green juice is touching. If that's where you are right now, take a breath. You're not alone, you're not broken, and you're also not necessarily fine — so let's talk about what's actually happening. Ibogaine is one of the heaviest hitters in the plant medicine and psychedelics world, with a deserved reputation for interrupting opioid addiction in a single session. But it's also the one most people underestimate on the back end. The trip ends. The recovery doesn't. And nobody at the retreat tends to send you home with a clear map for week two, week three, or month three — which is exactly when a lot of folks start quietly panicking. Most psychedelics clear your system in hours. Ibogaine does not play by those rules. The active compound metabolizes into noribogaine, which hangs around in fatty tissue and can keep influencing your nervous system for days, sometimes weeks. People report mood shifts, ataxia (that drunk-walking feeling), tinnitus, and cardiac irregularities well past the point they expected to feel normal. This isn't a bug — it's part of why ibogaine works for addiction recovery in the first place. The slow taper of noribogaine seems to ease the withdrawal cliff that breaks most people trying to come off opioids. The trade-off is that you're essentially convalescing from something the body genuinely had to work to process. Treat it like minor surgery, not like a hangover. Half-life estimates vary wildly between individuals. Body composition, liver enzymes (specifically CYP2D6), dose, and what you came in with all matter. Someone with a slow CYP2D6 phenotype can metabolize ibogaine dramatically slower than the person who sat next to them in ceremony. Two people, same dose, very different week-three experiences. Here's the rough territory most people land in. Not medical advice — just patterns I've heard from facilitators, integration coaches, and dozens of people who've come through the other side. Most of this is your nervous system recalibrating. The neural pathways that ibogaine seems to soften and rewire don't reset on a tidy schedule. If a friend who's never done plant medicine asks how you are and you say “still catching up to myself,” that's roughly the right answer for several weeks. Now the part nobody loves talking about. Some symptoms warrant a doctor — not a shaman, not a Reddit thread, an actual cardiologist or GP. Ibogaine has well-documented effects on the QT interval (a measurement of heart rhythm), and on rare occasions those effects don't snap back to baseline as fast as they should. Get medical attention if you're experiencing any of the following past the two-week mark: Ask for an ECG. Mention ibogaine specifically — most cardiologists won't have heard of it, but they'll know what to do once you describe what was taken and when. Bring documentation from your retreat if you have it. If you don't, write down what you remember: dose (in mg or flood/booster terminology), date, body weight at the time, any pre-screening labs they ran. This information will save you and the doctor a lot of fumbling. The instinct after a heavy psychedelic experience is to throw everything at the wall — supplements, gym sessions, cold plunges, three different therapists. Resist. Your system is already doing a lot. The kindest thing you can do is reduce inputs, not pile them on. What actually helps in the first month post-ibogaine: What to avoid: alcohol (full stop, for at least a month), other psychedelics (no “topping up” the experience, this is how people get hurt), SSRIs unless your prescriber has cleared the timing, and any stimulant — including pre-workout powders — until you've had a clean cardiac check. Here's the thing nobody tells you when you're booking an ibogaine retreat: the ceremony is the easiest part. The hard, slow, unsexy work is what happens in the weeks and months after, when you're back in your kitchen wondering if anything actually changed. People who do well long-term tend to share a few habits. They don't try to interpret the experience too quickly. They write things down without forcing meaning onto them. They stay connected to a small handful of people who get it. And they treat the post-ceremony months as protected time — they don't book a vision quest in Peru three weeks after their ibogaine session because they read about it on a forum at 3 a.m. If you came to ibogaine for opioid addiction, the integration window is also when relapse risk quietly creeps back. The window of reduced craving is real, but it's not infinite. Use the time. Build the structure — meetings, sponsor, therapist, exercise, accountability — that the medicine cleared space for. The medicine opened the door. You still have to walk through it, every day. An honest word: ibogaine isn't magic. It's an extraordinary tool with real risks, and it's the start of a process, not the conclusion of one. People who treat it as a single transaction — pay the money, take the medicine, problem solved — tend to be the same people who end up disappointed three months later, or worse, back in the patterns they came to interrupt. Some of the master plants and psychedelic medicines in this space work better as a sequence rather than a one-off. Ayahuasca after ibogaine. Psilocybin for ongoing depression work. San Pedro for grounding and integration. None of this is prescription — it's the lived pattern from people who've made meaningful changes stick. The medicine that finally moved something in you may not be the same medicine that helps you keep that ground. For readers wanting to take their healing further, a curated range of ibogaine, ayahuasca, and other plant medicine retreats can be browsed on our marketplace here. Take your time choosing — a good retreat will welcome your questions about screening, aftercare, and what happens at week three.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
